Follicle dynamics and anovulation in polycystic ovary syndrome

Size: px
Start display at page:

Download "Follicle dynamics and anovulation in polycystic ovary syndrome"

Transcription

1 Human Reproduction Update, Vol.14, No.4 pp , 2008 Advance Access publication May 22, 2008 doi: /humupd/dmn015 Follicle dynamics and anovulation in polycystic ovary syndrome Stephen Franks 1,3, Jaroslav Stark 2 and Kate Hardy 1 1 Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Hospital, London W12 0NN, UK; 2 Department of Mathematics, Imperial College London, London SW7 2AZ, UK 3 Correspondence address. s.franks@imperial.ac.uk BACKGROUND: Polycystic ovary syndrome (PCOS) is the commonest cause of anovulatory infertility and menstrual cycle abnormalities, but the factors responsible for failure to select a dominant follicle remain unclear. METHOD: Source is authors own studies and search of the relevant literature. RESULTS: Arrest of antral follicle growth is associated with an abnormal endocrine environment involving hypersecretion of luteinizing hormone and insulin (and perhaps hyperandrogenism). The net effect is secondary suppression of FSH, which leads to inhibition of maturation of otherwise healthy follicles in the cohort. There is, however, emerging evidence for an intrinsic abnormality of folliculogenesis in PCOS that affects the very earliest, gonadotrophin independent, stages of follicle development. There is an increased density of small pre-antral follicles and an increased proportion of early growing follicles. These abnormalities in anovulatory PCOS are further defined by abnormal granulosa cell proliferation and disparate growth of oocyte and surrounding granulosa cells. This suggests that the normal dialogue between oocyte and granulosa cells in these early growing follicles is altered. There is evidence that abnormal, local (follicle-to-follicle) signalling of anti-müllerian hormone may play a part in disordered folliculogenesis, but it is plausible that other local regulators that have been implicated in normal and abnormal pre-antral follicle development such as insulin-like growth factors and sex steroids have a role in aberrant folliculogenesis in PCOS. CONCLUSIONS: Significant abnormalities in the very earliest stages of folliculogenesis may be the root cause of anovulation in PCOS. Keywords: mathematical modelling; statistics; assisted reproduction Introduction Polycystic ovary syndrome (PCOS) is the commonest endocrine disorder in women of reproductive age. In its classic form a combination of oligo/anovulation and hyperandrogenism it is estimated to affect.5% of the female population (Franks, 1995; Knochenhauer et al., 1998; Asuncion et al., 2000; Azziz et al., 2004; Ehrmann, 2005). It is the major cause of anovulatory infertility, menstrual disturbances and hirsutism. PCOS is also associated with a metabolic disturbance, central to which is peripheral insulin resistance and compensatory hyperinsulinaemia (Dunaif, 1997; Ehrmann, 2005). These metabolic abnormalities have implications both for reproductive function and for long-term health. Although the most commonly recognized clinical manifestation of PCOS is the combination of symptoms of anovulation with those of androgen excess, it has become increasingly apparent that the spectrum of presentation of women with PCOS can be extended to embrace, on the one hand, women with anovulatory cycles (or amenorrhoea) who do not have clinical evidence of androgen excess (but who frequently have elevated serum concentrations of androgens) and, on the other, women with hirsutism who have regular, ovulatory cycles (Adams et al., 1986; Conway et al., 1989; Franks, 1989, 1995; Rotterdam, 2004a). These clinical categories are not necessarily rigid; it is not uncommon for subjects with polycystic ovaries and androgen excess to experience a mixture of ovulatory and anovulatory cycles (Baird et al., 1977; Yen, 1980; Franks, 1995) or, indeed, to change from a predominately anovulatory pattern to a mainly ovulatory picture (or vice versa) as may be seen, e.g. with changes in body weight (see below). The recognition of the wider range of symptomatic presentation of women with polycystic ovaries is the main motivation that prompted a re-evaluation of the diagnostic criteria for PCOS at a joint meeting between the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) in Rotterdam in May The resulting Rotterdam consensus statement presented revised criteria for diagnosis, the merits of which have been extensively debated elsewhere (Rotterdam, 2004a, b; Azziz, 2006; Azziz et al., 2006; Franks, 2006). Nevertheless, there is evidence that the resulting phenotypic subgroups do indeed represent varying manifestations of the same syndrome, but there are also interesting differences between the subgroups (Dewailly et al., 2006; Welt et al., 2006; Barber et al., 2007; Norman et al., 2007) that may # The Author Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org 367

2 Franks et al. shed some light on the mechanism of anovulation, as will be discussed later in this article. This review is focused on the key features and possible mechanisms of abnormal folliculogenesis and anovulation in PCOS. We will not include a discussion of the clinical management of anovulation, which has been the subject of several recent reviews. Importantly, the proceedings of the recent 2nd ESHRE/ASRM consensus conference on PCOS, on the subject of induction of ovulation, are to appear shortly in both Human Reproduction and Fertility and Sterility (ESHRE/ASRM, 2008a, b). Methods For this review, we drew on published and unpublished data from our own laboratory, an in-house library of relevant publications and a PubMed search which included the terms follicle development in PCOS and anovulation in PCOS. Endocrine and metabolic features of anovulatory women with PCOS The typical endocrine abnormalities of anovulatory women with PCOS are raised serum concentrations of androgens and luteinizing hormone (LH), with normal, or slightly suppressed serum FSH levels (Yen, 1980; Franks, 1995). Interestingly, elevated circulating LH and androgens are not specific to women with anovulation; they are also observed in hirsute women with polycystic ovaries and regular cycles (Adams et al., 1986; Franks, 1989, 1995), although LH concentrations tend to be higher in anovulatory cycles, due to failure of the negative feedback signal that is normally exerted by cyclical changes in estradiol and, in particular, progesterone. But there is an important difference in the metabolic profile of anovulatory compared with ovulatory women with PCOS and hyperandrogenism: insulin resistance and hyperinsulinaemia are features of anovulatory but not ovulatory subjects (Dunaif et al., 1987; Conway et al., 1989; Robinson et al., 1993; Barber et al., 2007). The association between anovulation and hyperinsulinaemia raises the question of a causal link between elevated insulin levels (and/or insulin resistance) and impaired ovulation. As discussed below, there is evidence that hyperinsulinaemia may indeed contribute to the mechanism of antral follicle dysfunction and anovulation in PCOS. Obesity has a significant impact on the clinical and endocrine presentation of women with PCOS (Conway et al., 1989; Kiddy et al., 1990). Overweight women with PCOS are more likely to be anovulatory and to have symptoms of androgen excess. Furthermore, obesity affects reproductive outcome in response to induction of ovulation (Balen et al., 2006; Legro et al., 2007). Conversely, diet and lifestyle intervention, resulting in reduced calorie intake and a weight reduction of as little as 5 10%, is a successful strategy in terms of restoring ovulation and fertility (Kiddy et al., 1992; Clark et al., 1995, 1998; Homan et al., 2007). The mechanism of the effects of obesity on reproductive function is complex, but hyperinsulinaemia and/or insulin resistance appear to play an important part. There is a disadvantageous interaction between PCOS and obesity in that although obesity is associated with reduced insulin sensitivity in normal women, obese women with PCOS are relatively more insulin resistant than BMI-matched 368 subjects with normal ovaries (Dunaif et al., 1987; Robinson et al., 1992; Franks, 1995; Dunaif, 1997; Ehrmann, 2005). It is unlikely, however, that hyperinsulinaemia is the only significant factor to explain anovulation. Lean women with oligo/anovulation and hyperandrogenism often have normal insulin secretion and sensitivity (but are more likely to show hypersecretion of LH than obese women with PCOS) (Conway et al., 1989; Taylor et al., 1997). The Rotterdam criteria for diagnosis have introduced a new category of subjects with PCOS, those with anovulation and polycystic ovaries who have neither clinical nor biochemical evidence of androgen excess (Dewailly et al., 2006; Welt et al., 2006; Barber et al., 2007; Norman et al., 2007). This subgroup is one that has attracted particular attention from those who are sceptical about the validity of the Rotterdam criteria (Azziz, 2006; Azziz et al., 2006), although, in our view, there is ample evidence to suggest that those women with polycystic ovaries and either estrogen-replete amenorrhoea or oligomenorrhoea are part of the same spectrum as those with anovulation and hyperandrogenism (Franks, 2006; Welt et al., 2006; Barber et al., 2007). Nevertheless, there is a striking difference in the metabolic profile between those with and without hyperandrogenism; the latter group have normal insulin levels and do not have reduced insulin sensitivity (Dewailly et al., 2006; Welt et al., 2006; Barber et al., 2007; Norman et al., 2007) (Fig. 1). Although the group with androgen excess are more obese than those without, the difference in insulin sensitivity remains significant after adjustment for BMI (Barber et al., 2007). In summary, endocrine and metabolic factors appear to have an influence on the development of anovulation in women with PCOS, but these factors do not exclude the possibility of an intrinsic abnormality of folliculogenesis in PCOS. Oocyte quality and fertility in PCOS Before discussing the characteristics of follicle development in PCOS and the relation to anovulation it is important to consider whether factors other than anovulation contribute to subfertility in women with PCOS. Broadly speaking, there is little evidence that either endometrial dysfunction or impaired oocyte function has a significant bearing on fertility. The most persuasive Figure 1: Insulin resistance, as measured by HOMA-IR, in subgroups of women with PCOS and controls subjects. The subgroups were anovulatory women with hyperandrogenaemia (anovpco (þha)) or anovulatory women with normal androgens (anovpco (2HA)). Values are geometric mean + SD. HOMA-IR was higher in anovpco (þha) than controls (P, ) but similar to controls in women without hyperandrogenaemia (Data from Barber et al., 2007).

3 support for this statement is that appropriate treatment to restore ovulation in anovulatory women with PCOS typically leads to normal cumulative conception rates [see consensus statement from the ESHRE/ASRM meeting, Thessaloniki, February, 2007 (ESHRE/ASRM, 2008a, b)]. Nevertheless, endometrial abnormalities in women with polycystic ovaries have been noted, including increased expression of androgen receptors (Apparao et al., 2002), and it remains possible that this has a small effect on fertility. A number of studies have investigated oocyte quality in women with polycystic ovaries undergoing assisted reproductive techniques. Although one study (using in vitro-matured oocytes) found that the rates of fertilization and normal embryo development were lower in women with PCOS than in those with regular cycles (Barnes et al., 1996), the weight of evidence suggests that the developmental potential of oocytes derived from women with PCOS is normal (Hardy et al., 1995; Mikkelsen and Lindenberg, 2001; Heijnen et al., 2006; Legro et al., 2007). As discussed in the next section, antral follicles in women with PCOS are heterogeneous and, in anovulatory subjects, include a proportion that has undergone premature arrest. The oocytes in such follicles are unlikely to have normal developmental potential but there remain sufficient healthy follicles to provide normal oocytes after superovulation. Abnormal antral follicle development and function The characteristic morphological feature of polycystic ovaries in anovulatory women is accumulation of antral follicles in the range of 2 8 mm in diameter (Franks et al., 2000). In other words, there is an apparent failure to select a dominant follicle and it is assumed that the larger antral follicles (5 8 mm) have been arrested in development. The simple explanation for this phenomenon is that serum concentrations of FSH, while rarely frankly low, are suppressed below the threshold level required during the early follicular phase to stimulate normal follicle maturation (Hillier, 1994). Indeed, increasing serum FSH (by treating with anti-estrogens or exogenous FSH) is the mainstay of successful induction of ovulation. The key question, however, is what is the reason for the suppression of FSH? Considerable insight into the mechanisms underlying abnormal follicle function has been obtained by systematic, predominately in vitro studies of the characteristics of antral follicles derived from polycystic ovaries. Abnormal folliculogenesis and anovulation in PCOS undergone several passages in culture (Nelson et al., 1999, 2001). Thus, theca cells from polycystic ovaries are characterized by constitutively increased activity of steroidogenic enzymes but this does not, of course, necessarily mean that such a phenotype represents the primary aetiological abnormality in PCOS. Many questions remain about the factors that control formation and activity of the theca cell layer during normal pre-antral folliculogenesis, let alone those involved in abnormal thecal development. Data presented later in this review suggest that the root of abnormal function of antral follicles may lie in the earliest stages of preantral follicle development. Granulosa Whereas there is little difference in the characteristics of theca cells between follicles obtained from ovulatory compared with anovulatory women with polycystic ovaries, there are major differences according to ovulatory status in granulosa cell steroidogenesis. These characteristics have been described in detail in primary publications and in previous reviews (Franks et al., 2000), but it is useful to summarize the findings here. The background to these studies was, at the time, the surprising observation that granulosa cells cultured from follicles derived from anovulatory women with PCOS were hyper-responsive to FSH in terms of estradiol production (Erickson et al., 1992; Mason et al., 1994) (Fig. 2). This seemed counter-intuitive given that impaired maturation of antral follicles is associated with suppressed activity of the enzyme P450 arom (aromatase). Although reduced aromatase activity can readily be explained by the suboptimal level of circulating FSH (rather than an intrinsic abnormality of granulosa cells), the exaggerated response to exogenous FSH [which has since been confirmed in in vivo studies (Wachs et al., 2006)] is harder to fathom. The answer to this paradox appears to lie in the marked heterogeneity of antral follicles in anovulatory PCOS. In subsequent experiments in our laboratory, granulosa cells were aspirated from individual follicles taken from unstimulated ovaries and cultured in the presence of FSH or LH. Granulosa cells from small to medium-sized antral follicles (1 9 mm in diameter) taken from women with ovulatory cycles and normal ovaries showed, as expected, a variable response to FSH and no Theca The most consistent biochemical abnormality in women with PCOS is hypersecretion of androgens (Franks, 1991) and there is now evidence that hyperandrogenism reflects an intrinsic abnormality of theca cell function. Primary cultures of theca cells isolated from polycystic ovaries (whether from anovulatory or ovulatory subjects) demonstrate greatly increased production of androgens (Gilling-Smith et al., 1994). These studies also showed that the production of intermediate steroids in the androgen biosynthetic pathway was increased, suggesting a global up-regulation of steroidogenic enzymes. Although it can be argued that such abnormalities could reflect the abnormal endocrine environment from which the cells were derived (e.g. higher than normal levels of LH and/or insulin), it is significant that a similar overall increase in steroidogenesis has been noted in theca cells that have Figure 2: Estradiol response to FSH (mean + SEM) in granulosa cells taken from follicles from ovaries of women with anovulatory PCOS or control subjects with normal ovaries and regular cycles. The response to FSH was significantly greater (P ¼ 0.03) in granulosa cells from PCOS compared with cells taken from normal ovaries (adapted from Mason et al., 1994). 369

4 Franks et al. response to LH in terms of production of estradiol and progesterone (Willis et al., 1998). Only granulosa cells taken from a larger (13 mm), dominant follicle, responded to LH. Cells derived from a similar spectrum of follicles from women with polycystic ovaries and regular cycles showed a very similar pattern, but there was a striking difference in the steroidogenic response of cells obtained from polycystic ovaries in women with chronic anovulation. The most important features were increased responsiveness, in terms of estradiol (and progesterone) production to FSH [echoing the results of previous studies (Erickson et al., 1992; Mason et al., 1994)] and inappropriate (premature) responsiveness to LH in some follicles as small as 2 4 mm. In addition there were high basal levels of these steroids with an exaggerated response to FSH and LH in a proportion of medium-sized antral follicles. Overall, there was much more heterogeneity of responsiveness among follicles from anovulatory women with PCOS than in the other two groups. In particular, small antral follicles (2 9 mm) from normal ovaries, and polycystic ovaries from ovulatory subjects were consistently unresponsive to LH but there was a much more variable response in follicles from polycystic ovaries in anovulatory women; some were inappropriately responsive to LH while others behaved as in normal ovaries (Willis et al., 1998).The implication of the premature responsiveness of granulosa cells in a proportion of small antral follicles is that inappropriate acquisition of LH receptors in granulosa cells (which in the normal follicular phase is confined to the dominant follicle) is likely to result in terminal differentiation in the granulosa layer (Hillier, 2001) and thence premature arrest of follicle growth. We have proposed that hyperinsulinaemia and/or hypersecretion of LH may contribute to the aberrant response of granulosa cells to LH and to the consequent arrest of follicle growth (Robinson et al., 1993; Willis et al., 1996; Franks et al., 2000). In a separate series of studies we demonstrated that pre-incubation of normal granulosa cells in the presence of insulin synergistically amplified the subsequent steroidogenic response to LH (Willis et al., 1996). It might be argued that higher than normal circulating concentrations of insulin would have a reduced impact in a state of peripheral insulin resistance but there is evidence that in classical insulin target tissues such as muscle, insulin resistance in PCOS is a post-receptor abnormality and is signalling pathway-specific (Dunaif et al., 1992, 1995; Corbould et al., 2005, 2006). It is likely that this phenomenon also applies to insulin action in the ovary. Results of studies of insulin effects in granulosa-lutein cells from women with anovulatory PCOS indicate that whereas glucose uptake and metabolism is impaired (Lin et al., 1997; Fedorcsak et al., 2000; Rice et al., 2005), insulin-stimulated steroidogenesis (progesterone production) is intact and similar to the response in cells from normal ovaries (Rice et al., 2005). The abnormal endocrine environment may therefore contribute to advancement of follicle maturation and premature arrest of development in a proportion of antral follicles, but this does not fully explain why healthy follicles within the cohort are unable to advance towards ovulation. The key to this suspension of normal follicle growth is the suppression of FSH, which can be reversed by judicious administration of low-dose FSH resulting in the growth and subsequent ovulation of a healthy dominant follicle (White et al., 1996; Homburg and Howles, 1999; Franks et al., 2000). Thus, anovulation in PCOS is characterized by increased responsiveness of some follicles to FSH and LH, 370 multiple follicle development, but arrested growth of antral follicles associated with suppression of serum FSH. On the face of it, the link between these phenomena and, in particular, the suppression of FSH is not easy to explain. Because of the negative non-linear feedback via the pituitary, the outcome of the interaction between a group of follicles during the selection phase is impossible to predict by intuition alone. In order to understand the integrated effect of these various factors, we therefore turned to mathematical modelling of follicle dynamics. Modelling follicle dynamics in PCOS Several models have been utilized to better understand unifollicular development and ovulation in the human cycle. The most extensively studied, and probably the best-known model has been developed by Lacker et al. (1987a, b). This is based on a simple feedback loop between ovary and pituitary whereby FSH stimulates follicle growth and estradiol production and as the level of estradiol in the circulation rises, it exerts negative feedback which leads to regression of all but the most responsive follicle. Lacker s model tracks the maturity of a cohort of follicles as a function of time through the selection phase (Fig. 3). To initialize the model, we assign two properties to each follicle: (i) its initial maturity as it enters the terminal phase, and (ii) its sensitivity to gonadotrophins for any given level of maturity. The sensitivity of a follicle is thus a function of its maturity, rather than just a single number. Note that even a low sensitivity follicle will respond strongly to gonadotrophins once it is mature enough. Lacker allows the initial maturity to vary between follicles, but assumes that all follicles have the same sensitivity function. He shows that in such a case it is possible to get robust selection of the ovulating follicle. Thus heterogeneity in follicle sensitivity to gonadotrophins is not necessary to reproduce a normal pattern of ovulation. By changing the follicle sensitivity it is possible to obtain ovulation of more than one follicle, corresponding to other species. Lacker s model can also exhibit a situation where a group of follicles arrest at a large size. It is even possible to choose sensitivity functions such that different choices of initial maturities lead either to arrest, or to ovulation. However, it can be mathematically proved that in such a model the number of follicles that can ovulate is always larger than the number that can arrest. Hence, if we initialized the model to exhibit the arrest of, say five follicles, minor variations in maturity or sensitivity would lead to cycles with at least six follicles ovulating. This is not consistent with human PCOS where one individual can show periods of arrest of a number of follicles interspersed with cycles where a single follicle ovulates. The only way that one obtain a model that can both exhibit ovulation of a single follicle (Fig. 3A) and arrest of a number of follicles (Fig. 3B) is to have a population of follicles with a mixture of different sensitivities (Chavez-Ross et al., 1997). Simulation, supported by mathematical theorems, then shows that if at the start of the cycle we have one or more sufficiently mature low sensitivity follicles, then one of these will dominate (Follicle 1 in Fig. 3A), suppressing all others which regress by atresia. This corresponds to a normal ovulatory cycles. On the other hand, if one or more follicles with higher sensitivity are

5 Abnormal folliculogenesis and anovulation in PCOS Figure 3: Mathematical modelling of follicle maturation in PCOS. Two simulations of a cohort of eight follicles in the follicular phase, showing how the outcome depends on a subtle balance between the initial maturities and sensitivities of the follicles at the start of the phase. Each given follicle has the same sensitivity in both (A) and (B), but the initial maturity is different. In (A) Follicle 1 is more mature than the others, but has relatively low sensitivity to gonadotrophins. It develops normally and ovulates, suppressing the other follicles that die by atresia. The same qualitative outcome would be observed if there were several low sensitivity follicles of similar maturity; only one of these would go on to ovulate. In contrast, in (B) Follicles 4 8, which are high sensitivity follicles, are more mature at the start of the cycle. This leads to an arrested state where these five follicles can persist at a large size indefinitely. The remaining follicles die by atresia as before. Both time and maturity are measured in arbitrary units (adapted from Chavez-Ross et al., 1997). relatively more mature at the start of the selection phase (Follicles 4 8 in Fig. 3B), then anovulatory arrest will result. This is because they too quickly reach a size where their estradiol output suppresses the other follicles from maturing. We emphasize that the only difference between Fig. 3A and B is the initial maturity of each follicle; all other properties of the model are identical. The precise outcome of each cycle depends subtly on the balance between maturity and sensitivity of the follicles at the start. If all follicles are low sensitivity then normal ovulatory cycles as in Fig. 3A will always result, if the majority of follicles are high sensitivity then arrest will usually occur as in Fig. 3B, and if there is a mixture in the ovary we may have periods of arrest interspersed with normal cycles. From this analysis, we can suggest the following conclusions about the nature of PCOS (Chavez-Ross et al., 1997): (i) the primary cause of follicular dysfunction is at the level of the ovary, rather than the pituitary, and is characterized by variable responsiveness of follicles to gonadotrophins; (ii) arrested follicles have different properties from healthy follicles (i.e. those that have the potential to ovulate). This is important because it implies that these properties may have already been determined during the pre-antral, gonadotrophin-independent stages of follicle development (see below); (iii) the abnormal response to gonadotrophins is best characterized by enhanced relative sensitivity to FSH (and LH) in a subpopulation of follicles (which of course is consistent with the observations from our experimental data) and (iv) those follicles that are hyper-responsive to gonadotrophins prematurely reach a level of maturity where they produce a sufficiently high concentration of circulating estradiol to suppress FSH to a level that is too low to encourage further development of healthy follicles in the cohort. Again, this conclusion is supported by observational data: in women with anovulatory PCOS, serum estradiol levels are slightly but significantly higher, and FSH lower, than in the normal early follicular phase. In summary, mathematical modelling provides a plausible pathway of interaction of follicular and endocrine factors that contribute to anovulation in PCOS but, as suggested in point (ii), the model raises the question of abnormal pre-antral follicle development. The mechanism by which abnormal early follicle development predisposes to later endocrine effects remains to be determined but one possible explanation is precocious acquisition of LH receptors in the granulosa layer. Abnormal pre-antral folliculogenesis in PCOS The gonadotrophin-dependent antral stages of follicle development represent only the latter few weeks in the life of a follicle. Progression of follicle development from the primordial (resting) stage to the late pre-antral stage in the human ovary probably takes several months (Gougeon, 1996; Hardy et al., 2000). Little is known about the factors that control initiation and progression of follicle growth in these early stages, but it is clear that local (paracrine and autocrine) factors are important and that gonadotrophins play little or no part (Gougeon, 1996). FSH receptors can be identified in granulosa cells as early as the primary stage of follicle growth (Oktay et al., 1997) [and there is evidence that FSH can enhance follicle development even at this stage (Wright et al., 1999)], but follicles are able to grow as far as the large pre-antral (or early antral) stage in the complete absence of bioactive FSH (Matthews et al., 1993). Data from studies of early follicle development in the rodent, domestic species and in primate ovaries suggest that growth factors of the transforming growth factor-b (TGFb) superfamily (Elvin et al., 2000; Pangas and Matzuk, 2004), insulin-like growth factors (IGFs) (Monget and Bondy, 2000) and sex steroids (Vendola et al., 1998; Skinner, 2005) may all be implicated in initiation and maintenance of follicle growth. It is also clear that a dialogue between oocyte and surrounding granulosa cells is a key element in normal follicle development (Eppig, 1991; Matzuk et al., 2002). Nevertheless, the critical factor (or combination of factors) involved remains to be clearly elucidated. In short, little is known about the regulation of pre-antral folliculogenesis in the normal human ovary, let alone in PCOS. 371

6 Franks et al. Our own recent studies of pre-antral follicle development in normal and polycystic ovaries were initially stimulated by a classic histological study published 25 years ago by Hughesdon (1982), a distinguished ovarian pathologist. He noted that, in histological ovarian sections taken from a series of women with normal and polycystic ovaries, there was not only an increase in the mean number of antral follicles per section in PCOS compared with normal ovaries, but that the number of primary and secondary follicles was also significantly higher in polycystic ovaries. These data clearly support the hypothesis that abnormalities of follicle development in PCOS may have their root in the early stages of growth. We had developed, in our laboratory, a method for studying pre-antral follicle development in small ovarian biopsies (Hovatta et al., 1999; Wright et al., 1999), obtained (with ethical approval and informed consent) from women undergoing routine laparoscopy. Tissue was fixed and prepared for histological examination either immediately after removal or after culture of pieces of tissue for up to 15 days. In the first study of early folliculogenesis in PCOS, we compared the morphological characteristics of tissue fixed immediately after removal from subjects with (i) normal ovaries and regular cycles (ii) polycystic ovaries and regular cycles and (iii) polycystic ovaries and oligomenorrhoea or amenorrhoea (Webber et al., 2003). The key findings are illustrated in Fig. 4. The density of pre-antral follicles (including primordial to multilayered preantal follicles) was significantly increased in tissue from anovulatory women with PCOS, mainly due to an increase in the primary follicle pool. The follicle density in biopsies taken from ovulatory subjects with polycystic ovaries was intermediate between the other two groups. A subsequent publication from the group of Dr Gregory Erickson confirmed the increased accumulation (what they termed stockpiling ) of primary follicles in polycystic ovaries (Maciel et al., 2004) and data from both studies are consistent with Hughesdon s earlier findings. An additional and novel finding in our study was the observation that the proportion of follicles that initiated growth was significantly higher (and the proportion of primordial follicles reciprocally lower) in polycystic ovary tissue (both from anovulatory and ovulatory women) compared with biopsies from normal ovaries. Thus, there is an important difference between normal and polycystic ovaries in the dynamics of early follicle development. The key questions arising from these data are (i) what is the cause of the increased density of small pre-antral follicles and (ii) what is the cause of the increased proportion of growing follicles in polycystic ovaries? More small pre-antral follicles in polycystic ovaries The increased density of pre-antral follicles could be explained by a higher initial population of primordial follicles in the polycystic ovary which, in turn, may result from one or more of three mechanisms: (i) more primordial germ cells entering the ovary during fetal life, (ii) more cell divisions (of germ cells or granulosa cells) which could lead to (iii) more follicles being formed (Webber et al., 2003) (Fig. 5). Another explanation for the larger stock of small pre-antral follicles and the longevity of this stock is that there is less follicle loss by atresia in polycystic ovaries (Fig. 5). 372 Figure 4: (A) density of pre-antral follicles (median, 95% CIs) in cortical biopsies from 22 women with normal ovaries, 14 ovulatory women with polycystic ovaries and 15 anovulatory women with polycystic ovaries. Total pre-antral follicle density (P ¼ 0.009) primary follicle density (P ¼ 0.004) were greater in biopsies from anovulatory women with polycystic ovaries than in tissue from normal ovaries. (B) proportions (95% CIs) of total healthy pre-antral follicles at primordial and primary stages. Both ovulatory (P ¼ 0.03) and anovulatory PCO groups (P ¼ 0.001) differed significantly from normal. (from Webber et al., 2003). We have used the human ovarian tissue slice culture system to study the growth and survival of pre-antral follicles in normal and polycystic ovaries (Webber et al., 2007). By culturing intact follicles within surrounding stroma, this system allows maintenance of normal interactions between oocyte, granulosa cells and thecal/stromal cells. Ovarian tissue was cultured for up to 15 days, then fixed in Bouin s solution, embedded in paraffin wax, serially sectioned and stained with haematoxylin and eosin. Follicles and enclosed oocytes were counted, measured and assessed for stage of development and health (i.e. categorized as either healthy or atretic). The proportion of atretic follicles was similar in biopsies from normal and polycystic ovaries in tissue fixed on the day of removal (Day 0), but during culture the proportion of atretic follicles was significantly lower in PCOS tissue (Webber et al., 2007) (Fig. 6). The reduced rate of follicle loss (or increased survival of follicles) in polycystic ovaries may therefore be an important contributory factor in the establishment of a higher density of pre-antral follicles in PCOS. Of course, the possible factor (or factors) responsible for the reduced rate of atresia in follicles from polycystic ovaries remains to be determined.

7 Abnormal folliculogenesis and anovulation in PCOS Figure 5: Fate of germ cells in the human fetal ovary and proposed mechanisms to explain increased density of small pre-antral follicles in the polycystic ovary. There may be a higher initial population of primordial follicles (red line) or a slower rate of loss by atresia (blue line) (or both) (from Webber et al., 2003). Figure 6: Increased survival in culture of preantral follicles from polycystic ovaries. Reduced proportion of atretic pre-antral follicles during culture of ovarian tissue for anovulatory women with PCOS (red) compared to tissue from women with normal ovaries (blue) (from Webber et al., 2007). reduction in the proportion of primordial follicles and a reciprocal increase in the proportion of growing follicles (Durlinger et al., 1999). These findings prompted us to explore the possibility that deficiency of AMH in small pre-antral follicles in polycystic ovaries contributes to disordered early folliculogenesis. Using immunohistochemistry, with a highly specific antibody to AMH, we studied the expression of AMH protein in sections of ovary obtained from archived human ovarian tissue (Stubbs et al., 2005). Ovaries were carefully classified as belonging to one of three groups, according to histological, clinical, ultrasonographic and biochemical data: normal ovaries (with history of regular cycles and evidence of ovulation), polycystic ovaries from women with regular cycles and polycystic ovaries from women with anovulatory cycles or amenorrhoea. AMH was localized in granulosa cells of follicles of all sizes (including small preantral follicles) but a significantly smaller proportion of primordial and transitional (early growing) follicles from polycystic ovaries derived from anovulatory women expressed AMH compared with the pattern of expression in women with either normal or polycystic ovaries who had a history of regular, ovulatory cycles (Fig. 7). Extrapolating from studies in the AMH null mouse (Durlinger et al., 1999), we therefore proposed that such a deficiency of AMH in early growing follicles would result in an inappropriate increase in the proportion of follicles entering the growing phase. In other words, the observed reduction in AMH expression in small pre-antral follicles could cause, or at least contribute to the cause of, disordered folliculogenesis and anovulation. These data may seem paradoxical given that a number of studies have shown that serum AMH concentrations are significantly higher in women with polycystic ovaries than in appropriate controls. However, the most abundant source of circulating AMH is small and medium-sized antral follicles and since this population of follicles is characteristically increased in polycystic ovaries and AMH production therefore significantly higher in polycystic than normal ovaries (refs). It is unlikely that any deficiency in the local production of AMH from small pre-antral follicles would be reflected in circulating AMH concentrations. In the mouse, exogenous AMH inhibits FSH-mediated follicle growth An increased proportion of growing follicles in PCOS a role for AMH? Just as the search for candidate molecules that contribute to the increased density of small pre-antral follicles continues, so too does the quest for likely candidates that are responsible for the higher than normal proportion of early growing follicles in polycystic ovaries. One such candidate is anti-müllerian hormone (AMH) which, in addition to its role during male sexual development, appears also to have an important role in the ovary. Expression of AMH, and the AMH-specific type 2 receptor in the ovary coincides with follicle growth (Ueno et al., 1989; Durlinger et al., 2002a, b), and there is good evidence that it is a key factor in regulating entry of follicles into the growing pool. Culturing mouse ovaries in the presence of AMH reduces the number of growing follicles (Durlinger et al., 2002a, b). In mice lacking the AMH gene, there is a Figure 7: Proportion (%) of pre-antral follicles staining positive for AMH by immunohistochemistry in sections of ovarian tissue from normal ovaries (green), polycystic ovaries from ovulatory women (blue) and from anovulatory women (red). The proportions of AMH positive primordial and transitional stages in anovulatory PCO were significantly lower (a: p ¼ ; b: p ¼ ) compared with the proportion in tissue from ovulatory subjects with either normal or polycystic ovaries (adapted from Stubbs et al., 2005). 373

8 Franks et al. (Durlinger et al., 2001). It is therefore conceivable that excess AMH produced by large pre-antral and small antral follicles plays a part in the aetiology of anovulation in PCOS but, as yet, there are no parallel data in human studies to support that hypothesis. It is unlikely, however, that the circulating high concentrations associated with PCOS have any significant impact on the relatively avascular cortical area in which is localized the vast majority of small pre-antral follicles. Nevertheless, the role of AMH as a paracrine signal in early follicle development in the human ovary remains open to question. One study found that mrna for the (specific) type 2 AMH receptor was detectable in only a small proportion of small pre-antral follicles (Rice et al., 2007). Clearly, further studies are needed to elucidate the effects of AMH in pre-antral human follicles. Granulosa cell proliferation in pre-antral follicles from normal and polycystic ovaries A key question invited by our observations of pre-antral follicle dynamics in polycystic ovaries is: does the increased proportion of small growing follicles in PCOS reflect increased granulosa cell division compared with normal ovaries? To address this question, we used a marker of cell division that has been used to identify proliferating cells in cancer studies, namely mini-chromosome maintenance protein-2 (MCM-2) (Madine et al., 2000; Scott et al., 2003; Laskey, 2005). MCM-2 binds to DNA and licenses DNA to replicate but ensures only one DNA replication per cycle. It persists throughout the cell cycle but is not present in quiescent (G0) or differentiated cells. We therefore considered this to be a good marker of proliferation in granulosa cells of early human preantral follicles. Once again, we used the archived human ovarian tissue to which we refer in the previous section, and performed systematic immunohistochemical analysis, using a specific antibody to human MCM-2 (Stubbs et al., 2007). We were interested to see that even primordial follicles showed a small proportion of MCM-2 positive granulosa cells, suggesting that, contrary to current dogma, primordial follicles are not completely quiescent and that there may be a low level of cell division even in the resting pool of follicles. However, at each stage of preantral follicle development, from primordial up to and including the primary stage, there was a higher proportion of MCM-2 positive follicles in tissue from anovulatory women with polycystic ovaries than in either of the two ovulatory groups (Fig. 8). Oocytes were significantly larger and there were more granulosa cells per follicle in transitional and primary follicles in the anovulatory PCOS group. Although the diameter of the oocyte was greater in these early pre-antral stages in follicles from anovulatory women with polycystic ovaries, there was a disparity in the relationship between oocyte growth and granulosa cell proliferation. The increase in the number of granulosa cells was disproportionately greater than the increase in oocyte diameter in the follicles from anovulatory polycystic ovaries, emphasizing the aberrant dynamics of early follicle development (Fig. 9). Candidate molecules in aberrant folliculogenesis The finding of clear evidence of accelerated granulosa cell proliferation during the initial stages of follicle development obviously raises the question, once again, of which molecules are responsible for in the abnormal regulation of early 374 Figure 8: Proportions (95% CIs) of MCM-2 positive follicles in sections of normal and polycystic ovaries. A higher proportion of follicles were MCM-2 positive in polycystic ovaries from women with anovulation (anovpco) than in tissue from either normal ovaries (P ¼ 0.013) or polycystic ovaries from women with regular cycles (ovpco, P ¼ ) (from Stubbs et al., 2007). Figure 9: Relationship between oocyte diameter and granulosa cell number in follicles from polycystic ovaries from women with anovulation (red), polycystic ovaries from women with regular cycles (blue) and in normal ovaries (green). The lines are non-linear fits; the curvature of the anovpco line is significantly different (P ¼ ) from the ovpco and normal lines (from Stubbs et al., 2007). folliculogenesis. As yet we have no clear answers to this question but there are data to suggest that both IGFs (El-Roeiy et al., 1994; Voutilainen et al., 1996; Vendola et al., 1998, 1999), and androgens may have a role. Studies of folliculogenesis in the Rhesus monkey ovary have indicated that androgens can stimulate initiation of follicle development and that this effect may be mediated by increased expression of the type 1 IGF receptor (Vendola et al., 1998, 1999). IGF-1 has been reported to stimulate growth of human pre-antral follicles in tissue culture (Louhio et al., 2000), and preliminary data from our own laboratory support these findings. Prenatal exposure to androgens is associated with aberrant folliculogenesis in the ovaries of offspring in both the Rhesus monkey and the sheep (Eisner et al., 2002; Steckler et al., 2005; Abbott et al., 2006; Dumesic et al., 2007; Forsdike et al., 2007), although recent data suggest that this action may not be a direct effect of testosterone but rather by metabolism to estradiol (Steckler et al., 2007). If androgens are implicated in aberrant folliculogenesis in the ovary, the critical question is: what is the source of excess androgen? It is most likely to be produced by theca cells of the ovary but since theca formation is a key element of normal follicle development, it is unclear whether excess production of androgen by theca

9 (an intrinsic abnormality in the polycystic ovary, as discussed above) is the primary abnormality or whether it is a function of abnormal pre-antral folliculogenesis. Some groups have turned to gene expression profiling of tissue from normal and polycystic ovaries to provide insight into the factors responsible for abnormal follicular function. As might be expected, the results highlighted several interesting metabolic pathways that were abnormally regulated in tissue from polycystic ovaries. In microarray studies of tissue (including theca, stroma, granulosa and oocytes) from women with normal and polycystic ovaries (as well as ovaries from testosterone-treated female to male transsexuals), dysregulated genes included those involved in Wnt signalling and in extracellular matrix formation (Jansen et al., 2004). Importantly, they noted that there was considerable overlap between the expression profiles of polycystic ovaries and those obtained after high-dose androgen treatment. In expression profiling of theca cell lines derived from polycystic ovaries, increased expression of genes encoding molecules involved in all-trans retinoic acid synthesis and in the transcription factor GATA-6 were among those differentially expressed when compared with cells from normal ovaries (Wood et al., 2003). In a very recently published study, microarray analysis of oocytes, obtained at the time of oocyte collection for in vitro fertilization, revealed differential expression of genes involved in chromosome segregation (Wood et al., 2007). Interestingly, many of the differentially expressed genes had putative androgen receptor binding elements, again suggesting that many of the differences between polycystic and normal ovaries in gene expression reflect downstream effects of exposure to excess androgen. Finally, some mention should be made about the search for candidate genes in PCOS and how that might provide clues to the nature of the factors involved in abnormal follicular function. To date, the results of candidate gene studies have proved largely disappointing (Franks and McCarthy, 2004; Nam Menke and Strauss, 2007; Urbanek, 2007). Recently, however, a locus on chromosome 19p has been reported to be associated with PCOS (Urbanek et al., 2005). Intriguingly, fine mapping of this locus puts it in the region of the gene coding for fibrillin 3 (FBN3) (Stewart et al., 2006). Fibrillins are extracellular matrix molecules primarily involved in tissue architecture (Isogai et al., 2003), but they are now known to have another role as regulators of TGFb growth factors (Hubmacher et al., 2006) and the possible relevance to early follicle development in the ovary should not be overlooked. Nevertheless, these results, fascinating though they might be, remain to be confirmed in other large genetic studies and, at present, the link between FBN3 and ovarian abnormalities in PCOS can best be described as informed speculation. Summary Abnormalities of follicle development in polycystic ovaries are most obviously manifest in the later, antral stages of the life of the follicle, and we have provided an explanation that links the abnormal endocrine environment and arrested antral follicle development with the mechanism of anovulation. It is clear, however, that abnormal follicle development is not confined to the gonadotrophin-dependent antral stages. There are significant abnormalities of the very earliest stages of folliculogenesis which are most marked in polycystic ovaries from women with a history of oligo- or anovulation, suggesting that such abnormalities are at the root of (or at least highly relevant to) the aetiology of anovulation. The cause of these early abnormalities is not yet clear but the unanswered questions are an undeniably strong stimulus for further research in this intriguing area of reproductive biology and endocrinology. Funding We are grateful to the Medical Research Council and the Wellcome Trust for funding much of the work from the authors laboratory reported in this review. References Abnormal folliculogenesis and anovulation in PCOS Abbott DH, Padmanabhan V, Dumesic DA. Contributions of androgen and estrogen to fetal programming of ovarian dysfunction. Reprod Biol Endocrinol 2006;4:17. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 1986;293: Apparao KB, Lovely LP, Gui Y, Lininger RA, Lessey BA. Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. Biol Reprod 2002;66: Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85: Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 2006;91: Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89: Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91: Baird DT, Corker CS, Davidson DW, Hunter WM, Michie EA, Van Look PF. Pituitary-ovarian relationships in polycystic ovary syndrome. J Clin Endocrinol Metab 1977;45: Balen AH, Platteau P, Andersen AN, Devroey P, Sorensen P, Helmgaard L, Arce JC. The influence of body weight on response to ovulation induction with gonadotrophins in 335 women with World Health Organization group II anovulatory infertility. Bjog 2006;113: Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol 2007;66: Barnes FL, Kausche A, Tiglias J, Wood C, Wilton L, Trounson A. Production of embryos from in vitro-matured primary human oocytes. Fertil Steril 1996;65: Chavez-Ross A, Franks S, Mason HD, Hardy K, Stark J. Modelling the control of ovulation and polycystic ovary syndrome. J Math Biol 1997;36: Clark AM, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X, Norman RJ. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995;10: Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 1998;13: Conway GS, Honour JW, Jacobs HS. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol (Oxf) 1989;30: Corbould A, Kim YB, Youngren JF, Pender C, Kahn BB, Lee A, Dunaif A. Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab 2005;288:E1047 E

METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY

METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY Vuk Vrhovac University Clinic Dugi dol 4a, HR-10000 Zagreb, Croatia Original Research Article Received: February 18, 2010 Accepted: March 3, 2010 METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN

More information

Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman

Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman Original Article Brunei Int Med J. 2012; 8 (5): 248-252 Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman Usha VARGHESE 1 and Shaji VARUGHESE 2, 1 Department of Internal Medicine

More information

ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)

ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing

More information

S. AMH in PCOS Research Insights beyond a Diagnostic Marker

S. AMH in PCOS Research Insights beyond a Diagnostic Marker S. AMH in PCOS Research Insights beyond a Diagnostic Marker Dr. Anushree D. Patil, MD. DGO Scientist - D National Institute for Research in Reproductive Health (Indian Council of Medical Research) (Dr.

More information

Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018

Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic

More information

PCOS What s new in Diagnosis & Treatment?

PCOS What s new in Diagnosis & Treatment? PCOS What s new in Diagnosis & Treatment? Roy Homburg Maccabi Medical Services and Barzilai Medical Centre, Ashkelon, Israel. Antalya, October, 2009 PCOS diagnosis - 1990 NIH criteria - Hyperandrogenism

More information

Developmental origin of polycystic ovary syndrome a hypothesis

Developmental origin of polycystic ovary syndrome a hypothesis 1 REVIEW Developmental origin of polycystic ovary syndrome a hypothesis D H Abbott, D A Dumesic 1 and S Franks 2 Department of Obstetrics and Gynecology and Wisconsin Regional Primate Research Centre,

More information

lbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour

lbt lab tests t Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour lbt lab tests t and Conrolled Ovarian Hyperstimulation Dr Soheila Ansaripour Research Instituteof Avicenna 4/23/2012 Why good prediction of poor response good prediction i of OHSS application appropriate

More information

Infertility Treatment in Polycystic Ovary Syndrome: Lifestyle Interventions, Medications and Surgery

Infertility Treatment in Polycystic Ovary Syndrome: Lifestyle Interventions, Medications and Surgery Macut D, Pfeifer M, Yildiz BO, Diamanti-Kandarakis E (eds): Polycystic Ovary Syndrome. Novel Insights into Causes Infertility Treatment in Polycystic Ovary Syndrome: Lifestyle Interventions, Medications

More information

Female Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF

Female Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve

More information

JMSCR Vol 05 Issue 05 Page May 2017

JMSCR Vol 05 Issue 05 Page May 2017 www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.14 Hyperinsulinemia in Polycystic Ovary Syndrome

More information

Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes

Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes POLYCYSTIC OVARY SYNDROME Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes Ettore Guastella, M.D., a Rosa Alba Longo, M.D., b and Enrico Carmina, M.D. b a Department

More information

Polycystic Ovary Syndrome

Polycystic Ovary Syndrome Polycystic Ovary Syndrome Definition: the diagnostic criteria Evidence of hyperandrogenism, biochemical &/or clinical (hirsutism, acne & male pattern baldness). Ovulatory dysfunction; amenorrhoea; oligomenorrhoea

More information

Polycystic Ovary Syndrome

Polycystic Ovary Syndrome Polycystic Ovary Syndrome What is Polycystic Ovarian Syndrome? Polycystic Ovarian Syndrome (PCOS) is characterized by the presence of multiple ovarian cysts and excess androgen production. Clinical Features

More information

Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Hospital, London, UK

Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Hospital, London, UK (2008) 32, 1035 1041 & 2008 Macmillan Publishers Limited All rights reserved 0307-0565/08 $30.00 www.nature.com/ijo PEDIATRIC REVIEW Institute of Reproductive and Developmental Biology, Imperial College

More information

Outlook PCOS: a diagnostic challenge

Outlook PCOS: a diagnostic challenge RBMOnline - Vol 8. No 6. 2004 644-648 Reproductive BioMedicine Online; www.rbmonline.com/article/1274 on web 5 April 2004 Outlook PCOS: a diagnostic challenge Dr Ricardo Azziz Dr Azziz is currently Chairman

More information

Overview of Reproductive Endocrinology

Overview of Reproductive Endocrinology Overview of Reproductive Endocrinology I have no conflicts of interest to report. Maria Yialamas, MD Female Hypothalamic--Gonadal Axis 15 4 Hormone Secretion in the Normal Menstrual Cycle LH FSH E2, Progesterone,

More information

Gonadotrophin treatment in patients with Polycystic Ovary Syndrome

Gonadotrophin treatment in patients with Polycystic Ovary Syndrome Int. J. Adv. Res. Biol. Sci. (218). 5(4): 95-99 International Journal of Advanced Research in Biological Sciences ISSN: 2348-869 www.ijarbs.com DOI: 1.22192/ijarbs Coden: IJARQG(USA) Volume 5, Issue 4-218

More information

The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria

The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria Prace oryginalne/original papers Endokrynologia Polska/Polish Journal of Endocrinology Tom/Volume 62; Numer/Number 3/2011 ISSN 0423 104X The prevalence of polycystic ovary syndrome in Iranian women based

More information

The reproductive lifespan

The reproductive lifespan The reproductive lifespan Reproductive potential Ovarian cycles Pregnancy Lactation Male Female Puberty Menopause Age Menstruation is an external indicator of ovarian events controlled by the hypothalamicpituitary

More information

The excess in 2 5 mm follicles seen at ovarian ultrasonography is tightly associated to the follicular arrest of the polycystic ovary syndrome

The excess in 2 5 mm follicles seen at ovarian ultrasonography is tightly associated to the follicular arrest of the polycystic ovary syndrome Human Reproduction Vol.22, No.6 pp. 1562 1566, 2007 Advance Access publication on April 20, 2007 doi:10.1093/humrep/dem060 The excess in 2 5 mm follicles seen at ovarian ultrasonography is tightly associated

More information

clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome

clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome & clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome Zulfo Godinjak¹*, Ranka Javorić² 1 Gynecology and Obstetrics

More information

Female androgen profiles by MS for PCOS patients. CS Ho APCCMS 2010, Hong Kong 14 January 2010

Female androgen profiles by MS for PCOS patients. CS Ho APCCMS 2010, Hong Kong 14 January 2010 Female androgen profiles by MS for PCOS patients CS Ho APCCMS 2010, Hong Kong 14 January 2010 873 women with increased serum androgens Androgen-secreting neoplasms 0.2% Classical CAH 0.6% Non-classical

More information

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)

More information

Polycystic Ovarian Syndrome (PCOS) LOGO

Polycystic Ovarian Syndrome (PCOS) LOGO Polycystic Ovarian Syndrome (PCOS) Ma qianhong Ob/Gyn Department LOGO Contents Epidemiology and Definition Pathophysiology, Endocrinological Features Diagnostic Criteria Treatment Prognosis Introduction

More information

OVARY The surface of the ovary is covered with surface epithelium

OVARY The surface of the ovary is covered with surface epithelium OVARY Cow The ovary, or female gonad, is: 1. an exocrine gland, producing oocytes 2. an endocrine gland, secreting hormones, i.e., estrogen and progesterone OVARY OVARY The surface of the ovary is covered

More information

Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization

Milder is better? Advantages and disadvantages of mild ovarian stimulation for human in vitro fertilization Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization Revelli et al. Reproductive Biology and Endocrinology 2011, 9:25 Presenter: R2 孫怡虹 Background

More information

Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome

Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome Endocrine Journal 2007, 54 (2), 233 238 Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome TAKESHI IWASA, TOSHIYA MATSUZAKI, MASAHIRO MINAKUCHI, NAOKO

More information

3. Metformin therapy for PCOS

3. Metformin therapy for PCOS 1. Introduction The key clinical features of polycystic ovary syndrome (PCOS) are hyperandrogenism (hirsutism, acne, alopecia) and menstrual irregularity with associated anovulatory infertility. 1 The

More information

Reproductive FSH. Analyte Information

Reproductive FSH. Analyte Information Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary

More information

Dr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain. Declared no potential conflict of interest

Dr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain. Declared no potential conflict of interest Dr. Ernesto Bosch Instituto Valenciano de Infertilidad Valencia, Spain Declared no potential conflict of interest Is there a role for LH in elderly patients? Dr. Ernesto Bosch Instituto Valenciano de Infertilidad.

More information

Polycystic ovarian syndrome: Are radiology departments contributing to the misdiagnosis?

Polycystic ovarian syndrome: Are radiology departments contributing to the misdiagnosis? Polycystic ovarian syndrome: Are radiology departments contributing to the misdiagnosis? Poster No.: C-1238 Congress: ECR 2010 Type: Scientific Exhibit Topic: Genitourinary Authors: G. Tony, N. V. Gurjar,

More information

Polycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology

Polycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology Polycystic Ovarian Syndrome Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology Outline Definition Symptoms Causal factors Diagnosis Complications Treatment Why are we talking about

More information

Female Reproductive Endocrinology

Female Reproductive Endocrinology Female Reproductive Endocrinology Dr. Channa Jayasena PhD MRCP FRCPath Clinical Senior Lecturer & Consultant Endocrinologist Department of Gynaecology, Hammersmith Hospital Anovulation is a common cause

More information

Reproduction. AMH Anti-Müllerian Hormone. Analyte Information

Reproduction. AMH Anti-Müllerian Hormone. Analyte Information Reproduction AMH Anti-Müllerian Hormone Analyte Information - 1-2011-01-11 AMH Anti-Müllerian Hormone Introduction Anti-Müllerian Hormone (AMH) is a glycoprotein dimer composed of two 72 kda monomers 1.

More information

Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs)

Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs) Abstract: Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs) Ashraf Olabi, Ghena Alqotini College of medicine, Aleppo University Hospital Obstetrics and Gynacology, Syria.

More information

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016 Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)

More information

The Egyptian Journal of Hospital Medicine (January 2018) Vol. 70 (8), Page

The Egyptian Journal of Hospital Medicine (January 2018) Vol. 70 (8), Page The Egyptian Journal of Hospital Medicine (January 2018) Vol. 70 (8), Page 1278-1288 Anti-Mullerian Hormone: An Indicator for the Severity of Polycystic Ovarian Syndrome Yehia Abd-Elsalam Wafa 1, Mohamed

More information

ENDOCRINE CHARACTERISTICS OF ART CYCLES

ENDOCRINE CHARACTERISTICS OF ART CYCLES ENDOCRINE CHARACTERISTICS OF ART CYCLES DOÇ. DR. SEBİHA ÖZDEMİR ÖZKAN KOCAELI UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF OBSTETRICS AND GYNECOLOGY, IVF UNIT 30.04.2014, ANTALYA INTRODUCTION The endocrine

More information

PCOS and Obesity DUB is better treated by OCPs

PCOS and Obesity DUB is better treated by OCPs PCOS and Obesity DUB is better treated by OCPs Dr. Ritu Joshi Senior consultant Fortis escorts Hospital, Jaipur Chairperson Family welfare com. FOGSI (20092012) Vice President FOGSI 2014 Introduction One

More information

WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED

WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED Ricardo Azziz, M.D., M.P.H., M.B.A. Chief Officer of Academic Health & Hospital Affairs State University of New York (SUNY)

More information

Reproductive outcome in women with body weight disturbances

Reproductive outcome in women with body weight disturbances Reproductive outcome in women with body weight disturbances Zeev Shoham M.D. Dep. Of OB/GYN Kaplan Hospital, Rehovot, Israel Weight Status BMI (kg/m 2 ) Underweight

More information

A Tale of Three Hormones: hcg, Progesterone and AMH

A Tale of Three Hormones: hcg, Progesterone and AMH A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Human Ovarian Steroidogenesis and Gonadotrophin Stimulation Johan

More information

Best practices of ASRM and ESHRE

Best practices of ASRM and ESHRE Best practices of ASRM and ESHRE Late submission Cortina d Ampezzo, Italy 1-3 March 2012 A joint meeting between the American Society for Reproductive Medicine and the European Society of Human Reproduction

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our

More information

In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome

In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Original Article Effect of Laparoscopic Ovarian Drilling on Outcomes of In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Maryam Eftekhar, M.D. 1, Razieh Deghani Firoozabadi,

More information

Endocrine control of female reproductive function

Endocrine control of female reproductive function Medicine School of Women s & Children s Health Discipline of Obstetrics & Gynaecology Endocrine control of female reproductive function Kirsty Walters, PhD Fertility Research Centre, School of Women s

More information

Disordered follicle development in ovaries of prenatally androgenized ewes

Disordered follicle development in ovaries of prenatally androgenized ewes 421 Disordered follicle development in ovaries of prenatally androgenized ewes Rachel A Forsdike, Kate Hardy, Lauren Bull, Jaroslav Stark 1, Lisa J Webber, Sharron Stubbs, Jane E Robinson 2 and Stephen

More information

Polycystic Ovary Syndrome

Polycystic Ovary Syndrome What is the polycystic ovary syndrome? Polycystic Ovary Syndrome The polycystic ovary syndrome (PCOS) is a clinical diagnosis characterized by the presence of two or more of the following features: irregular

More information

Developmental Programming: Impact of Prenatal Androgenization on Nonhuman and Human Primates. Daniel A. Dumesic, M.D.

Developmental Programming: Impact of Prenatal Androgenization on Nonhuman and Human Primates. Daniel A. Dumesic, M.D. Developmental Programming: Impact of Prenatal Androgenization on Nonhuman and Human Primates Daniel A. Dumesic, M.D. Professor, Department of Obstetrics and Gynecology Chief, Division of Reproductive Endocrinology

More information

The role of growth factors in regulating cellular events during ovarian follicular development Leon J. Spicer

The role of growth factors in regulating cellular events during ovarian follicular development Leon J. Spicer The role of growth factors in regulating cellular events during ovarian follicular development Leon J. Spicer Department of Animal Science, Oklahoma State University, Stillwater, OK USA SESSION #54 EAAP

More information

CASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?

CASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen? CASE 41 A 19-year-old woman presents to her gynecologist with complaints of not having had a period for 6 months. She reports having normal periods since menarche at age 12. She denies sexual activity,

More information

REPRODUCTIVE CYCLE OF FEMALE MAMMAL

REPRODUCTIVE CYCLE OF FEMALE MAMMAL REPRODUCTIVE CYCLE OF FEMALE MAMMAL Fig. 8-12 Secondary follicles growing follicles increase in number of layers of granulosa cells Tertiary follicles maturing follicles antrum formation fluid filled space

More information

The menstrual cycle. François Pralong

The menstrual cycle. François Pralong The menstrual cycle François Pralong Services d Endocrinologie, Diabétologie et Métabolisme, Hôpitaux Universitaires de Genève et Lausanne Centre des Maladies CardioVasculaires et Métaboliques, Lausanne

More information

Editorial 2. Polycystic Ovary Syndrome: From in utero to Menopause INTRODUCTION GENETICS OF PCOS IN UTERO FETAL PROGRAMMING

Editorial 2. Polycystic Ovary Syndrome: From in utero to Menopause INTRODUCTION GENETICS OF PCOS IN UTERO FETAL PROGRAMMING Editorial 2 Polycystic Ovary Syndrome: From in utero to Menopause INTRODUCTION The syndrome of polycystic ovaries is typically diagnosed during the adolescent period or during the reproductive years, when

More information

The menstrual Cycle. François Pralong

The menstrual Cycle. François Pralong The menstrual Cycle François Pralong Services d Endocrinologie, Diabétologie et Métabolisme, Hôpitaux Universitaires de Genève et Lausanne Centre des Maladies CardioVasculaires et Métaboliques, Lausanne

More information

www.iffs-reproduction.org @IntFertilitySoc Int@FedFertilitySoc Conflict of interest none Outline Causes of ovulatory dysfunction Assessment of women with ovulatory dysfunction Management First line Second

More information

Academic Sciences. Asian Journal of Pharmaceutical and Clinical Research

Academic Sciences. Asian Journal of Pharmaceutical and Clinical Research Academic Sciences Asian Journal of Pharmaceutical and Clinical Research Vol 5, Issue 3, 202 ISSN - 0974-244 Research Article A COMPARATIVE STUDY ON THE EFFECTIVENESS OF SINGLE AND COMBINATION THERAPIES

More information

and a common association with insulin resistance

and a common association with insulin resistance OBESITY Clinical Medicine 2015 Vol 15, No 6: s72 s76 Polycystic ovar y syndrome: insight into pathogenesis and a common association with insulin resistance Authors: T ho m a s M B a r b e r, A G e o rg

More information

Obstretics and Gynaecology. Nikita M. Singh A, Deepak Kamat B, Parth Patel A, Tupe N.B C

Obstretics and Gynaecology. Nikita M. Singh A, Deepak Kamat B, Parth Patel A, Tupe N.B C Original Article National Journal of Medical and Dental Research, Jan.-March. 2017: Volume-5, Issue-2, Page 112-117 DEMOGRAPHIC PROFILE, PREVALENCE AND TREATMENT MODALITIES RECEIVED BY PATIENTS WITH POLYCYSTIC

More information

LH activity administration during the

LH activity administration during the LH activity administration during the luteal-follicular transition Richard Fleming On behalf of the Luveris Pre-treatment group University of Glasgow Scotland Androgens have a Paracrine action in the Early

More information

Concept : effects by treatment

Concept : effects by treatment QuickTime and a TIFF (LZW) decompressor are needed to see this picture. ESHRE CAMPUS 2010 MARIBOR INFLUENCE of stimulation on oocyte quality? Johan Smitz, MD, PhD UZBrussel Vrije Universiteit Brussel Brussels,

More information

THYROID PROFILE IN POLYCYSTIC OVARIAN SYNDROME Sudhanshu Sekhara Nanda 1, Subhalaxmi Dash 2, Ashok Behera 3, Bharati Mishra 4

THYROID PROFILE IN POLYCYSTIC OVARIAN SYNDROME Sudhanshu Sekhara Nanda 1, Subhalaxmi Dash 2, Ashok Behera 3, Bharati Mishra 4 THYROID PROFILE IN POLYCYSTIC OVARIAN SYNDROME Sudhanshu Sekhara Nanda 1, Subhalaxmi Dash 2, Ashok Behera 3, Bharati Mishra 4 HOW TO CITE THIS ARTICLE: Sudhanshu Sekhara Nanda, Subhalaxmi Dash, Ashok Behera,

More information

Prevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study

Prevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study Prevalence of Anovulation in Subfertile Women in Kerbala 2012, A descriptive Cross-Sectional Study Mousa Mohsen Ali* Wasan Ghazi* HayderAamerAbboud^ *Kerbala University, College of Medicine, Gynecology

More information

Metformin in early pregnancy and abortions. Laure Morin-Papunen, MD, PhD Dept. of Obstetrics and Gynecology University Hospital of Oulu, Finland

Metformin in early pregnancy and abortions. Laure Morin-Papunen, MD, PhD Dept. of Obstetrics and Gynecology University Hospital of Oulu, Finland Metformin in early pregnancy and abortions Laure Morin-Papunen, MD, PhD Dept. of Obstetrics and Gynecology University Hospital of Oulu, Finland PCOS and miscarriage risk Metformin and miscarriage risk

More information

12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman

12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman Polycystic Ovarian Syndrome (PCOS) for the Family Physician Barbara S. Apgar MD, MS Professor or Family Medicine University of Michigan Ann Arbor, Michigan Important references for PCOS Endocrine Society

More information

Study of clinical presentation in cases of Polycystic Ovarian Syndrome in rural population

Study of clinical presentation in cases of Polycystic Ovarian Syndrome in rural population Original article: Study of clinical presentation in cases of Polycystic Ovarian Syndrome in rural population 1Dr Shalini Kanotra, 2 Dr Nikita Singh*, 3 Dr V B Bangal 1 Associate Professor, OBGY Department,

More information

Effect of Resistin on Granulosa and Theca Cell Function in Cattle

Effect of Resistin on Granulosa and Theca Cell Function in Cattle 1 Effect of Resistin on Granulosa and Theca Cell Function in Cattle D.V. Lagaly, P.Y. Aad, L.B. Hulsey, J.A. Grado-Ahuir and L.J. Spicer Story in Brief Resistin is an adipokine that has not been extensively

More information

Polycystic ovary syndrome (PCOS) Polycystic ovary syndrome: Why are women at increased risk of type 2 diabetes? Article.

Polycystic ovary syndrome (PCOS) Polycystic ovary syndrome: Why are women at increased risk of type 2 diabetes? Article. Article Polycystic ovary syndrome: Why are women at increased risk of type 2 diabetes? Julie Tomlinson Citation: Tomlinson J (2016) Polycystic ovary syndrome: Why are women at increased risk of type 2

More information

Original Investigation. 94 Endocrine Oncology and Metabolism. Jovanovska et al

Original Investigation. 94 Endocrine Oncology and Metabolism. Jovanovska et al Original Investigation Sensitivity and specificity of anti-mülerian hormone in the diagnosis of polycystic ovary syndrome in a macedonian population of women of reproductive age: a cross-sectional study

More information

Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc)

Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Guideline for the Investigation and Management of Polycystic Ovary Syndrome Author: Contact Name and Job Title

More information

Nature and Science 2017;15(8)

Nature and Science 2017;15(8) Prognostic Value of Day 3 Luteinising Hormone (LH) in the prediction of Ovarian Response in Patients with Polycystic Ovary syndrome Mohammed Samir Fouad 1 ; Mohammed Said El-Shorbagy 2, Mohammed Mohammed

More information

The intra-follicular molecular biology mandating advancement of egg retrieval in some women

The intra-follicular molecular biology mandating advancement of egg retrieval in some women The intra-follicular molecular biology mandating advancement of egg retrieval in some women David H. Barad, USA Director of Assisted Reproductive Technology, The Center for Human Reproduction New York

More information

Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women

Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women Human Reproduction Vol.23, No.8 pp. 1924 1931, 2008 Advance Access publication on June 24, 2008 doi:10.1093/humrep/den239 Clinical and biochemical characteristics of polycystic ovary syndrome in Korean

More information

What every dermatologist should know about Polycystic Ovary Syndrome (PCOS)

What every dermatologist should know about Polycystic Ovary Syndrome (PCOS) What every dermatologist should know about Polycystic Ovary Syndrome (PCOS) Kanade Shinkai, MD PhD University of California, San Francisco Associate Professor of Dermatology I have no conflicts of interest

More information

Reproductive Medicine and Surgery Unit, University of Sheffield, Sheffield Teaching Hospitals, Jessop Wing, Tree Root Walk, Sheffield S10 2SF, UK 2

Reproductive Medicine and Surgery Unit, University of Sheffield, Sheffield Teaching Hospitals, Jessop Wing, Tree Root Walk, Sheffield S10 2SF, UK 2 RBMOnline - Vol 19. No 4. 2009 572 576 Reproductive BioMedicine Online; www.rbmonline.com/article/4100 on web 19 August 2009 Article How common is polycystic ovary syndrome in recurrent miscarriage? Dr

More information

Occurrence of polyovular follicles and its possible significance in the ovary of the bat, Scotophilus heathi

Occurrence of polyovular follicles and its possible significance in the ovary of the bat, Scotophilus heathi Biol Res 31: 75-80 (1998) Occurrence of polyovular follicles and its possible significance in the ovary of the bat, Scotophilus heathi UP SINGH, J DOVAL and A KRISHNA* Department of Zoology, Bañaras Hindu

More information

Addressing Practice Gaps in PCOS

Addressing Practice Gaps in PCOS Addressing Practice Gaps in PCOS PCOS Challenge September 21, 2014 Ricardo Azziz, MD, MPH, MBA President, Georgia Regents University CEO, Georgia Regents Health System Introduction PCOS research began

More information

Diagnostic features of polycystic ovary syndrome

Diagnostic features of polycystic ovary syndrome REVIEW article Diagnostic features of polycystic ovary syndrome 3 N Barday-Karbanee, MB ChB, DTM&H, BSc Hons (Reprod Biol) Berg Medicross, Newville, Johannesburg T I Siebert, MMed (O&G), FCOG M H Botha,

More information

CREATING A PCOS TREATMENT PLAN. Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University

CREATING A PCOS TREATMENT PLAN. Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University CREATING A PCOS TREATMENT PLAN Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University PCOS: CREATING A TREATMENT PLAN Good treatment plans are based on sound and complete evaluations History of

More information

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D., a Bart C. J. M. Fauser, M.D., Ph.D., b Joop S. E. Laven,

More information

Ovarian Steroidogenic Abnormalities in the Polycystic Ovary Syndrome

Ovarian Steroidogenic Abnormalities in the Polycystic Ovary Syndrome Chapter 18 / Steroidogenesis in PCOS 203 18 Ovarian Steroidogenic Abnormalities in the Polycystic Ovary Syndrome Denis A. Magoffin SUMMARY Excess androgen biosynthesis is a diagnostic feature of polycystic

More information

The Effects of Exercise and Nutritional Counseling. in Women with Polycystic Ovary Syndrome. A Thesis Submitted to the College of

The Effects of Exercise and Nutritional Counseling. in Women with Polycystic Ovary Syndrome. A Thesis Submitted to the College of The Effects of Exercise and Nutritional Counseling in Women with Polycystic Ovary Syndrome A Thesis Submitted to the College of Graduate Studies and Research in Partial Fulfillment of the Requirements

More information

Polycystic Ovary Disease: A Common Endocrine Disorder in Women

Polycystic Ovary Disease: A Common Endocrine Disorder in Women Polycystic Ovary Disease: A Common Endocrine Disorder in Women Paul Kaplan, M.D. Clinical Professor of Reproductive Endocrinology - OHSU Courtesy Senior Research Associate, Human Physiology University

More information

IVM in PCOS patients. Introduction (1) Introduction (2) Michael Grynberg René Frydman

IVM in PCOS patients. Introduction (1) Introduction (2) Michael Grynberg René Frydman IVM in PCOS patients Michael Grynberg René Frydman Department of Obstetrics and Gynecology A. Beclere Hospital, Clamart, France Maribor, Slovenia, 27-28 February 2009 Introduction (1) IVM could be a major

More information

The emergence of Personalized Medicine protocols for IVF.

The emergence of Personalized Medicine protocols for IVF. Individualising IVF: Introduction to the POSEIDON Concept Introduction The emergence of Personalized Medicine protocols for IVF. Differences between patients: age, ovarian reserve, BMI or presence of ovarian

More information

Clinical Profile Polycystic Ovarian Syndrome Cases

Clinical Profile Polycystic Ovarian Syndrome Cases ORIGINAL RESEARCH www.ijcmr.com - 100 Cases Himabindu Sangabathula 1, Neelima Varaganti 1 ABSTRACT Introduction: Polycystic ovary syndrome (PCOS) is most common endocrine disorders of reproductive age

More information

A guide to understanding polycystic ovary syndrome (PCOS)

A guide to understanding polycystic ovary syndrome (PCOS) REVIEW A guide to understanding polycystic ovary syndrome (PCOS) Editor s choice Scan to access more free content W Colin Duncan Scottish Senior Clinical Fellow and Consultant in Reproductive Medicine,

More information

Update on Polycystic Ovary Syndrome What Dermatology Nurses and Nurse Practitioners Need to Know

Update on Polycystic Ovary Syndrome What Dermatology Nurses and Nurse Practitioners Need to Know FEATURE ARTICLE Update on Polycystic Ovary Syndrome What Dermatology Nurses and Nurse Practitioners Need to Know Rebecca Carron 2.0 Contact Hours ABSTRACT Purpose: Polycystic ovary syndrome is the most

More information

Do aromatase inhibitors have a place in IVF?

Do aromatase inhibitors have a place in IVF? Do aromatase inhibitors have a place in IVF? Roy Homburg Maccabi Medical Services and Barzilai Medical Centre, Ashkelon, Israel Antalya, September, 2009 Human Follicle Growth Primordial follicle 1 layer

More information

Developmental Programming: Impact of Prenatal Androgenization on Nonhuman and Human Primates. Daniel A. Dumesic, M.D.

Developmental Programming: Impact of Prenatal Androgenization on Nonhuman and Human Primates. Daniel A. Dumesic, M.D. Developmental Programming: Impact of Prenatal Androgenization on Nonhuman and Human Primates Daniel A. Dumesic, M.D. Professor, Department of Obstetrics and Gynecology Chief, Division of Reproductive Endocrinology

More information

AEPCOS NewSLET TER A N D R O G E N E X C E S S & P C O S S O C I E T Y. V o l u m e 2, I s s u e 12 D E C E M B E R 3 1,

AEPCOS NewSLET TER A N D R O G E N E X C E S S & P C O S S O C I E T Y. V o l u m e 2, I s s u e 12 D E C E M B E R 3 1, AEPCOS NewSLET TER A N D R O G E N E X C E S S & P C O S S O C I E T Y D E C E M B E R 2 0 1 4 n e w s l e t t e r S M O K I N G I N W O M E N W I T H P C O S This issue newsletter reports the final program

More information

Mohammad. Renad zakaria ---

Mohammad. Renad zakaria --- 13 Mohammad Renad zakaria --- Before we start: - I didn t follow the record order, for organizing purposes. - I added extra information from our text box which is Guyton 12 th edition, pages 987-997, actually

More information

Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound

Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound Human Reproduction vol.12 no.5 pp. 905 909, 1997 Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound E.Carmina 1, L.Wong 2, L.Chang 2, R.J.Paulson 2, disturbance of the IGF/IGFBP-l

More information

Role of inositol in Reproductive Function

Role of inositol in Reproductive Function Role of inositol in Reproductive Function Dr. Mirudhubashini Govindarajan, FRCSC Clinical Director Womens Center Coimbatore HYPE OR HOPE???? Inositol an Introduction Inositol has 10 types of isomers Myo

More information

Polycystic ovary syndrome

Polycystic ovary syndrome Jon Havelock, MD, FRCSC Polycystic ovary syndrome Therapy for this reproductive and metabolic disorder remains focused on managing symptoms, including infertility caused by anovulation, and reducing long-term

More information

S.Fisher 1,3, A.Grin 2, A.Paltoo 2 and H.M.Shapiro 2

S.Fisher 1,3, A.Grin 2, A.Paltoo 2 and H.M.Shapiro 2 Human Reproduction Vol.20, No.1 pp. 84 88, 2005 Advance Access publication October 15, 2004 doi:10.1093/humrep/deh543 Falling estradiol levels as a result of intentional reduction in gonadotrophin dose

More information

The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (1), Page 63-69

The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (1), Page 63-69 The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (1), Page 63-69 Effect of Metformin Only versus Effect of Metformin and Corticosteroids after Laparoscopic Ovarian Drilling on Ovulation

More information

Clinical Study Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS

Clinical Study Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS International Endocrinology Volume 2012, Article ID 434830, 5 pages doi:10.1155/2012/434830 Clinical Study Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS Kim Forrester-Dumont,

More information

Objectives 06/21/18 STILL A PLACE FOR PILLS DON T IVF EVERYTHING. Clomiphene citrate and Letrozole. Infertility Case Studies. Unexplained Infertility

Objectives 06/21/18 STILL A PLACE FOR PILLS DON T IVF EVERYTHING. Clomiphene citrate and Letrozole. Infertility Case Studies. Unexplained Infertility STILL A PLACE FOR PILLS DON T IVF EVERYTHING Jeff Roberts M.D. Co-Director, Pacific Centre for Reproductive Medicine Objectives 1 2 3 4 5 Clomiphene citrate and Letrozole Infertility Case Studies Unexplained

More information